UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 2018
Commission File Number: 001-37965
TiGenix
(Translation of registrant's name into English)
Romeinse straat 12
3001 Leuven, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [ X ]
ITEM 1 – INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Attached as Exhibit 99.1 is a copy of the press release of TiGenix dated June 19, 2018.
ITEM 2 – EXHIBITS
The following exhibits are filed as a part of this report:
| Exhibit Number | Description | |
| 99.1 | Press Release dated June 19, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TIGENIX | |||
| Date: June 19, 2018 | By: | /s/ Eduardo Bravo | |
| Name: | Eduardo Bravo Fernández de Araoz | ||
| Title: | Chief Executive Officer | ||
EXHIBIT 99.1
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007
REGULATED INFORMATION
PRESS RELEASE
Transparency notifications
pursuant to Article 14 of the Law of May 2, 2007
Leuven (Belgium) - June 19, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
Summary of the notifications
It concerns the following two notifications:
1. Content of the notification of Takeda Pharmaceutical Company Limited and Grifols, S.A.
Date of the notification: June 11, 2018.
Reason of the notification: acquisition or disposal of voting securities or voting rights / termination of an agreement to act in concert.
Persons subject to the notification requirement: Takeda Pharmaceutical Company Limited (with address at 1-1 Doshomachi 4-Chome, Chuo-ku, Osaka 540-8645, Japan), who is a parent undertaking/controlling person and who is acting in concert with Grifols S.A. (with address at Avenida de la Generalitat 152, 08147 Sant Cugat de Vallès, Barcelona, Spain), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: June 8, 2018.
Threshold that was crossed: 90% (Takeda Pharmaceutical Company Limited); 3% (Grifols, S.A.).
Denominator: 296,067,856.
Details of the notification: following the acquisition of voting securities or voting rights, the number of voting rights was as follows:
subtotal: 268,309,029 voting rights (90.62% of the total number of voting rights).
Chain of controlled undertakings through which the holdings are effectively held: 1. Takeda Pharmaceuticals International AG is controlled by Takeda Pharma A/S, which is controlled by Takeda A/S, which is controlled by Takeda Pharmaceutical Company Limited and by Takeda Europe Holdings B.V., which is controlled by Takeda Pharmaceutical Company Limited. 2. Gri-Cel, S.A. is controlled by Instituto Grifols, S.A., which is controlled by Grifols, S.A. 3. Grifols Worldwide Operations Ltd. is controlled by Grifols, S.A.
2. Content of the notification of Bank of America Corporation
Date of the notification: June 18, 2018.
Reason of the notification: acquisition or disposal of financial instruments that are treated as voting securities / downward crossing of the lowest threshold.
Person subject to the notification requirement: Bank of America Corporation (with address at Wilmington, D.E., United States), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: June 11, 2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: following the disposal of financial instruments that are treated as voting securities, the number of voting rights was as follows:
and the number of equivalent financial instruments was as follows:
Chain of controlled undertakings through which the holding is effectively held: Merrill Lynch Professional Clearing Corporation and Bank of America, National Association are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.
This press release and the above-mentioned transparency notifications can be consulted on our website:
For more information:
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel (darvadstrocel), previously Cx601, received European Commission (EC) approval for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Alofisel for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com.